Semaglutide Effective in High-Risk Diabetic Kidney Disease
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.
A Japanese study showed that light to moderate alcohol drinkers had a significantly decreased risk for chronic kidney disease compared with those who drank no alcohol.
In a study of Swedish women, gestational diabetes that progressed to type 2 diabetes was significantly associated with increased risks for chronic kidney disease and end-stage kidney disease.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
In a study of patients on dialysis, investigators found no higher risk for retinal hemorrhages and other ophthalmic problems among roxadustat-treated patients compared with patients receiving darbepoetin alfa.
Compared with azathioprine, rituximab decreased the risk of another relapse by 70% among patients who had experienced relapse and received re-induction of remission with rituximab, a study showed.
In a propensity score matched analysis, patients with a history of acute kidney injury (AKI) had a significant 43% lower risk of kidney stones than those who never experienced AKI.
The risk of hyperkalemia recurrence in patients with chronic kidney disease increases for each hyperkalemia episode a person experiences.
Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.
Patients with heart failure who remained on mineralocorticoid receptor antagonists after a hyperkalemia episode had a lower risk for major cardiovascular events than those who stopped taking the medications, a study found.